Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Accenture
AstraZeneca
Baxter
Cerilliant
Moodys
Express Scripts
Federal Trade Commission
Johnson and Johnson
Novartis

Generated: August 17, 2017

DrugPatentWatch Database Preview

Upsher-smith Labs Company Profile

« Back to Dashboard

What is the competitive landscape for UPSHER-SMITH LABS, and when can generic versions of UPSHER-SMITH LABS drugs launch?

UPSHER-SMITH LABS has sixty-two approved drugs.

There are ten US patents protecting UPSHER-SMITH LABS drugs on UPSHER-SMITH LABS drugs in the past three years.

There are twenty-two patent family members on UPSHER-SMITH LABS drugs in nine countries.

Summary for Applicant: Upsher-smith Labs

Patents:10
Tradenames:45
Ingredients:40
NDAs:62
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher-smith Labs
DIVALPROEX SODIUM
divalproex sodium
TABLET, DELAYED RELEASE;ORAL078182-001Jul 29, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
VOGELXO
testosterone
GEL;TRANSDERMAL204399-002Jun 4, 2014AB2RXNoNo► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
FLUVOXAMINE MALEATE
fluvoxamine maleate
TABLET;ORAL075887-002Jan 5, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
MORPHINE SULFATE
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL202104-003Jun 3, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Upsher-smith Labs
FLUVOXAMINE MALEATE
fluvoxamine maleate
TABLET;ORAL075887-003Jan 5, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for UPSHER-SMITH LABS drugs

Drugname Dosage Strength Tradename Submissiondate
topiramate
Extended-release Capsules25 mg, 50 mg, 100 mg, 150 mg, and 200 mg
QUDEXY XR
12/24/2015
calcitonin-salmon (recombinant)
Nasal Spray200 IU/spray
FORTICAL
3/29/2006

Non-Orange Book Patents for Upsher-smith Labs

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,662,340Testosterone gel compositions and related methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Upsher-smith Labs Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0156594► Subscribe
Canada2857286► Subscribe
China1422160► Subscribe
Israel246134► Subscribe
Australia3660401► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Upsher-smith Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
00375Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
C/GB95/010United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
12/018Ireland► SubscribePRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Federal Trade Commission
McKesson
Fuji
Queensland Health
Medtronic
Julphar
Daiichi Sankyo
Citi
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot